| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 821 | 2005 |
| Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy F Muntoni, M Cau, A Ganau, R Congiu, G Arvedi, A Mateddu, MG Marrosu, ... New England Journal of Medicine 329 (13), 921-925, 1993 | 516 | 1993 |
| Selective expression of adhesion molecules on human brain microvascular endothelial cells MF Stins, F Gilles, KS Kim Journal of neuroimmunology 76 (1-2), 81-90, 1997 | 403 | 1997 |
| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1268-1283. e6, 2018 | 216 | 2018 |
| Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS GL Mancardi, R Saccardi, M Filippi, F Gualandi, A Murialdo, M Inglese, ... Neurology 57 (1), 62-68, 2001 | 197 | 2001 |
| Overexpression of the cytokine BAFF and autoimmunity risk M Steri, V Orrù, ML Idda, M Pitzalis, M Pala, I Zara, C Sidore, V Faà, ... New England Journal of Medicine 376 (17), 1615-1626, 2017 | 192 | 2017 |
| Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72 A Chiò, G Borghero, G Restagno, G Mora, C Drepper, BJ Traynor, ... Brain 135 (3), 784-793, 2012 | 190 | 2012 |
| Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis S Sanna, M Pitzalis, M Zoledziewska, I Zara, C Sidore, R Murru, ... Nature genetics 42 (6), 495-497, 2010 | 190 | 2010 |
| Prospective study of multiple sclerosis with early onset A Ghezzi, C Pozzilli, M Liguori, MG Marrosu, N Milani, C Milanese, ... Multiple Sclerosis Journal 8 (2), 115-118, 2002 | 190 | 2002 |
| Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene MG Marrosu, S Vaccargiu, G Marrosu, A Vannelli, C Cianchetti, F Muntoni Neurology 50 (5), 1397-1401, 1998 | 187 | 1998 |
| Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia MG Marrosu, R Murru, MR Murru, G Costa, P Zavattari, M Whalen, ... Human molecular genetics 10 (25), 2907-2916, 2001 | 182 | 2001 |
| Age‐related disability in multiple sclerosis M Trojano, M Liguori, G Bosco Zimatore, R Bugarini, C Avolio, D Paolicelli, ... Annals of Neurology: Official Journal of the American Neurological …, 2002 | 171 | 2002 |
| DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population MG Marrosu, MR Murru, G Costa, R Murru, F Muntoni, F Cucca Human molecular genetics 7 (8), 1235-1237, 1998 | 160 | 1998 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 158 | 2017 |
| Sardinian multiple sclerosis is associated with HLA‐DR4: A serologic and molecular analysis MG Marrosu, F Muntoni, MR Murru, G Spinicci, MP Pischedda, F Goddi, ... Neurology 38 (11), 1749-1749, 1988 | 158 | 1988 |
| Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis MP Amato, E Portaccio, A Ghezzi, B Hakiki, V Zipoli, V Martinelli, L Moiola, ... Neurology 75 (20), 1794-1802, 2010 | 155 | 2010 |
| Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity C Sardu, E Cocco, A Mereu, R Massa, A Cuccu, MG Marrosu, P Contu PloS one 7 (3), e32487, 2012 | 146 | 2012 |
| Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and-DR4 alleles. MG Marrosu, MR Murru, G Costa, F Cucca, S Sotgiu, G Rosati, F Muntoni American journal of human genetics 61 (2), 454, 1997 | 141 | 1997 |
| A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. F Muntoni, L Wilson, G Marrosu, MG Marrosu, C Cianchetti, L Mestroni, ... The Journal of clinical investigation 96 (2), 693-699, 1995 | 134 | 1995 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 128 | 2017 |
